Related posts

Top Biotech and Pharma Stocks to Bet on Cancer Cure & ControlBiotechnology, Gene-editing and Medical Research Stocks to Buy in 2019Top Stocks with Groundbreaking Potential in the DNS Manipulation and Gene-Editing Markets
Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

Experts have mixed opinions on CRISPR Therapeutics AG. Some believe that the company's gene technology presents potential for growth, while others are cautious due to their limited knowledge of the science and business. Recent improvements in R&D have been a major gain for the business, but the unpredictable nature of health discoveries makes it difficult to predict the future. Overall, the company's potential is viewed with both optimism and caution by different experts.

Consensus
Mixed
Valuation
Fair Value
COMMENT

Is trading at a fraction of a few years ago. If you know about gene technology, maybe buy this, but doesn't know a lot about this science or business.

biotechnology
BUY

They have some explosive technology. He believes in it.

biotechnology
HOLD

Recent improvements in R&D have been major gain in the business. Is hard to predict future of business given nature of health discoveries. Would recommend holding it. 

biotechnology
DON'T BUY
Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.
biotechnology
RISKY
A great spec. It's a genetic engineering company so it's bought on spec, not earnings.
biotechnology
COMMENT
A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)
biotechnology
COMMENT
They produce a gene-editing tool that splices DNA that has the potential of curing diseases such as Huntington's Chorea and cancer. It's new technology, but he can't think of another company doing this. This segment is very rich and a trading opportunity at best.
biotechnology
Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

CRISPR Therapeutics AG(CRSP-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 2

Stockchase rating for CRISPR Therapeutics AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CRISPR Therapeutics AG(CRSP-Q) Frequently Asked Questions

What is CRISPR Therapeutics AG stock symbol?

CRISPR Therapeutics AG is a American stock, trading under the symbol CRSP-Q on the NASDAQ (CRSP). It is usually referred to as NASDAQ:CRSP or CRSP-Q

Is CRISPR Therapeutics AG a buy or a sell?

In the last year, 2 stock analysts published opinions about CRSP-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CRISPR Therapeutics AG.

Is CRISPR Therapeutics AG a good investment or a top pick?

CRISPR Therapeutics AG was recommended as a Top Pick by on . Read the latest stock experts ratings for CRISPR Therapeutics AG.

Why is CRISPR Therapeutics AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CRISPR Therapeutics AG worth watching?

2 stock analysts on Stockchase covered CRISPR Therapeutics AG In the last year. It is a trending stock that is worth watching.

What is CRISPR Therapeutics AG stock price?

On 2024-11-15, CRISPR Therapeutics AG (CRSP-Q) stock closed at a price of $47.25.